When antivirals backfire: An evaluation of favipiravir’s clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study

Background: Favipiravir is an oral antiviral, that might treat COVID-19 by enhancing viral eradication, particularly in patients with mild-to-moderate disease. Yet, the findings on the use of favipiravir in critically ill patients with COVID-19 are inconsistent. Therefore, this study aimed to assess...

Full description

Bibliographic Details

Published in:	Journal of Infection and Public Health
Main Authors:	Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Mashael AlFaifi, Majed Nahari, Alaa Almagthali, Abrar K. Thabit, Raghad Alhajaji, Reham Alharbi, Khawla Kahtani, Abeer A. Alenazi, Aisha Alharbi, Munirah M. Alghwainm, Sara M. Alotaibi, Yazeed S. Alghamdi, Samar Alotaibi, Shaden H. Alonazi, Jumanah M. Almutairi, Ramesh Vishwakarma
Format:	Article
Language:	English
Published:	Elsevier 2023-09-01
Subjects:	Favipiravir Mortality MV duration, Length of stay (LOS), COVID-19 SARS-CoV-2 Intensive care units Critically ill
Online Access:	http://www.sciencedirect.com/science/article/pii/S1876034123002162